Holen Sie sich die Stockscreener-App
2.15
7.33%
-0.17
Handel nachbörslich:
2.13
-0.02
-0.93%
Schlusskurs vom Vortag:
$2.32
Offen:
$2.3
24-Stunden-Volumen:
131.30K
Relative Volume:
1.48
Marktkapitalisierung:
$29.29M
Einnahmen:
$10.16M
Nettoeinkommen (Verlust:
$-47.57M
KGV:
-0.2609
EPS:
-8.24
Netto-Cashflow:
$-42.73M
1W Leistung:
-1.83%
1M Leistung:
-12.60%
6M Leistung:
-29.74%
1J Leistung:
-66.30%
1-Tages-Spanne:
$2.09
$2.4821
1-Wochen-Bereich:
$2.09
$2.4821
52-Wochen-Spanne:
$1.02
$8.29
Curis Inc Stock (CRIS) Company Profile
Firmenname
Curis Inc
Sektor
Branche
Telefon
617-503-6500
Adresse
128 SPRING STREET, LEXINGTON, MA
Vergleichen Sie CRIS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
2.15 | 29.29M | 10.16M | -47.57M | -42.73M | -8.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-11-17 | Eingeleitet | Truist | Buy |
| 2022-04-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2020-07-29 | Eingeleitet | Laidlaw | Buy |
| 2020-07-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-08-11 | Eingeleitet | FBR Capital | Outperform |
| 2015-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-21 | Bestätigt | ROTH Capital | Buy |
| 2014-05-09 | Bestätigt | Oppenheimer | Outperform |
| 2013-10-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2013-09-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2012-11-14 | Eingeleitet | Stifel Nicolaus | Hold |
| 2012-01-31 | Bestätigt | Brean Murray | Buy |
| 2012-01-31 | Bestätigt | Summer Street Research | Buy |
| 2011-12-09 | Eingeleitet | Oppenheimer | Outperform |
| 2011-10-06 | Eingeleitet | Summer Street Research | Buy |
| 2011-09-22 | Eingeleitet | MLV Capital | Buy |
| 2011-03-21 | Bestätigt | Brean Murray | Buy |
| 2010-02-26 | Bestätigt | Roth Capital | Buy |
| 2010-01-07 | Eingeleitet | Roth Capital | Buy |
Alle ansehen
Curis Inc Aktie (CRIS) Neueste Nachrichten
Millennium Management LLC Boosts Stake in Curis, Inc. (NASDAQ:CRIS) - Defense World
Cantor Fitzgerald Forecasts Curis FY2026 Earnings - Defense World
Squarepoint Ops LLC Invests $35,000 in Curis, Inc. (NASDAQ:CRIS) - Defense World
Curis : Reports First Quarter 2020 Financial Results - marketscreener.com
Curis : to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020 - marketscreener.com
CRISCuris Provides First Quarter 2025 Business Update - mx.advfn.com
Canada Goose, Planet Fitness, Curis, Goodyear, Sunrun: Trending by Analysts - MSN
Curis Approves Key Amendments at Annual Meeting - TipRanks
What is HC Wainwright’s Estimate for Curis Q2 Earnings? - Defense World
Curis (NASDAQ:CRIS) Receives Buy Rating from HC Wainwright - Defense World
Curis (CRIS) Sees Positive Rating Action from HC Wainwright & Co. | CRIS Stock News - GuruFocus
Curis assumed with a Buy at H.C. Wainwright - TipRanks
H.C. Wainwright sets $17 target for Curis stock with Buy rating - Investing.com Nigeria
Curis (CRIS) Sees Positive Rating Action from HC Wainwright & Co - GuruFocus
Curis (CRIS) Gains Buy Rating with Promising Cancer Therapy Deve - GuruFocus
Curis Provides Third Quarter 2023 Business Update - Seeking Alpha
Curis (NASDAQ:CRIS) Now Covered by Analysts at StockNews.com - Defense World
FY2025 EPS Estimates for Curis Reduced by Cantor Fitzgerald - Defense World
Curis highlights progress in lymphoma and AML trials with expanded patient enrollment - MSN
Curis, Inc. (NASDAQ:CRIS) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Ardent Health Partners, Inc. (ARDT) and Agilon Health (AGL) - The Globe and Mail
Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com - Defense World
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates - MSN
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | CRIS Stock News - GuruFocus
Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Improvements and Strategic Developments - Yahoo Finance
Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Imp - GuruFocus
Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Improvements and Strategic Developments By GuruFocus - Investing.com Canada
Curis Inc. Reports Q1 2025 Progress and Financials - TipRanks
Curis Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Curis Inc. Earnings Call: Clinical Advances Amid Cash Concerns - TipRanks
Curis: Q1 Earnings Snapshot - MySA
Curis Q1 2025 Earnings Call Transcript - MarketBeat
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GuruFocus
Curis, Inc. (CRIS) Advances Emavusertib Studies with Positive Da - GuruFocus
Curis (CRIS) Strengthens Leadership with New Chief Medical Officer | CRIS Stock News - GuruFocus
Curis appoints Ahmed Hamdy as Chief Medical Officer - TipRanks
Curis reports Q1 EPS ($1.25), consensus ($1.26) - TipRanks
Earnings call transcript: Curis Inc. Q1 2025 sees stock surge despite losses - Investing.com India
Curis Provides First Quarter 2025 Business Update - StreetInsider
Curis (CRIS) Expands Leadership and Advances Clinical Studies | - GuruFocus
Curis Provides First Quarter 2025 Business Update | CRIS Stock N - GuruFocus
Curis Inc (CRIS) Q1 2025 Earnings: EPS of -$1.25 Misses Estimates, Revenue of $2.4M Falls Short - GuruFocus
Curis (CRIS) Expands Leadership and Advances Clinical Studies | CRIS Stock News - GuruFocus
Curis Provides First Quarter 2025 Business Update | CRIS Stock News - GuruFocus
CURIS INC SEC 10-Q Report - TradingView
Finanzdaten der Curis Inc-Aktie (CRIS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):